About InCarda Therapeutics
InCarda Therapeutics is a company based in Palo Alto (United States) founded in 2009. InCarda Therapeutics has raised $79.7 million across 6 funding rounds from investors including Innoviva, Deerfield and Healthcap. InCarda Therapeutics offers products and services including Orally Inhaled Flecainide. InCarda Therapeutics operates in a competitive market with competitors including Portola Pharma, MyoKardia, Cellino, Arrakis Therapeutics and Tenaya Therapeutics, among others.
- Headquarter Palo Alto, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Incarda Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$79.7 M (USD)
in 6 rounds
-
Latest Funding Round
$30 M (USD), Series C
Oct 21, 2020
-
Investors
Innoviva
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of InCarda Therapeutics
InCarda Therapeutics offers a comprehensive portfolio of products and services, including Orally Inhaled Flecainide.
Inhaled drug for managing acute paroxysmal atrial fibrillation episodes.
People of InCarda Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of InCarda Therapeutics
InCarda Therapeutics has successfully raised a total of $79.7M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $30 million completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in InCarda Therapeutics
InCarda Therapeutics has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Innoviva, Deerfield and Healthcap.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Multiple sectors are invested in by Morningside, a VC fund.
|
Locked | Locked | Locked |
Investor details for InCarda Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by InCarda Therapeutics
Investment portfolio details for InCarda Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - InCarda Therapeutics
Detailed financials for InCarda Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Incarda Therapeutics Comparisons
Peer comparison for InCarda Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of InCarda Therapeutics
InCarda Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Portola Pharma, MyoKardia, Cellino, Arrakis Therapeutics and Tenaya Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for cardiovascular and autoimmune diseases are developed.
|
|
| Locked | Locked | Locked |
Specialized drugs are developed for genetic heart diseases.
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
|
| Locked | Locked | Locked |
Provider of tools for the analysis of RNA structures
|
|
| Locked | Locked | Locked |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| Locked | Locked | Locked |
Innovative pharmaceuticals for cardiovascular and metabolic diseases are developed.
|
Detailed competitors of InCarda Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Incarda Therapeutics
Complete news archive for InCarda Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about InCarda Therapeutics
InCarda Therapeutics was founded in 2009 and raised its 1st funding round 3 years after it was founded.
InCarda Therapeutics is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
InCarda Therapeutics is a funded company, having raised a total of $79.7M across 6 funding rounds to date.
InCarda Therapeutics was founded in 2009 in Palo Alto, United States, within the biotechnology sector focused on cardiovascular treatments. Operations center on innovative inhalation-based delivery of drugs directly to cardiac tissue, enabling rapid onset and reduced off-target exposure. The lead product, InRhythm, is an inhaled therapy under development for symptomatic paroxysmal atrial fibrillation, utilizing approved drugs for patient-administered use.
InCarda Therapeutics's top competitors include Tenaya Therapeutics, Cellino and MyoKardia.
InCarda Therapeutics offers Orally Inhaled Flecainide.
InCarda Therapeutics has 7 investors. Key investors include Innoviva, Deerfield, Healthcap, Morningside, and Morningside China.